苑东生物 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	1.4B	1.1B	1.2B	1.0B	922.0M
Revenue Growth %	20.9%	-4.6%	14.5%	11.0%	--
Total Revenue	1.4B	1.1B	1.2B	1.0B	922.0M
Cost Of Revenue	338.0M	223.0M	196.0M	143.0M	105.0M
+Gross Profit	1.0B	894.0M	975.0M	880.0M	817.0M
Gross Margin %	75.0%	80.0%	83.3%	86.0%	88.6%
Total Operating Cost	1.2B	954.0M	1.0B	884.0M	800.0M
Selling Expenses	446.0M	385.0M	474.0M	468.0M	472.0M
Admin Expenses	107.0M	98.9M	90.3M	60.0M	54.1M
Rd Expenses	264.0M	238.0M	231.0M	201.0M	154.0M
Finance Expenses	-14.3M	-11.2M	-10.2M	-3.9M	-3.1M
+Operating Income	252.0M	242.0M	261.0M	244.0M	199.0M
Operating Margin %	18.7%	21.7%	22.3%	23.9%	21.6%
Non Operating Income	1.4M	104,200	1.5M	8.2M	501,700
Non Operating Expenses	781,000	201,500	166,800	5.5M	246,200
Investment Income	9.8M	10.9M	7.9M	28.4M	9.5M
Fair Value Change Income	14.9M	14.6M	20.0M	13.7M	--
Asset Disposal Income	-3,000	133,300	257,300	--	5,600
Asset Impairment Loss	5.7M	2.6M	2.3M	1.9M	2.0M
Other Income	48.1M	53.1M	65.0M	62.7M	67.4M
Income Before Tax	253.0M	242.0M	262.0M	247.0M	199.0M
Income Tax	14.4M	15.1M	15.5M	14.5M	20.9M
+Net Income	238.0M	227.0M	247.0M	232.0M	178.0M
Net Margin %	17.6%	20.3%	21.1%	22.7%	19.3%
Net Income Attributable	238.0M	227.0M	247.0M	232.0M	178.0M
Eps Basic	1.36	1.28	2.05	1.94	1.78
Eps Diluted	1.36	1.28	2.05	1.94	1.78

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	971.0M	781.0M	831.0M	1.1B	1.1B
Trading Financial Assets	452.0M	742.0M	516.0M	454.0M	570.0M
Accounts Receivable	177.0M	120.0M	137.0M	112.0M	121.0M
Notes Receivable	17.6M	14.1M	6.1M	6.3M	4.3M
Notes And Accounts Receivable	195.0M	134.0M	143.0M	119.0M	126.0M
Prepayments	14.7M	8.8M	15.9M	18.0M	9.5M
Inventory	190.0M	161.0M	141.0M	104.0M	84.0M
Total Current Assets	1.9B	1.9B	1.7B	1.8B	1.9B
Long Term Equity Investment	22.7M	24.6M	24.7M	--	--
Fixed Assets	--	1.1B	910.0M	237.0M	199.0M
Fixed Assets Total	1.1B	1.1B	910.0M	237.0M	199.0M
Construction In Progress	--	186.0M	231.0M	638.0M	373.0M
Construction In Progress Total	190.0M	186.0M	231.0M	638.0M	373.0M
Intangible Assets	35.6M	34.5M	34.6M	33.7M	34.2M
Long Term Deferred Expenses	3.7M	4.9M	3.0M	4.3M	3.4M
Total Non Current Assets	1.5B	1.5B	1.3B	996.0M	637.0M
Total Assets	3.4B	3.3B	3.0B	2.8B	2.5B
Short Term Borrowings	74.4M	181.0M	105.0M	20.0M	40.0M
Accounts Payable	109.0M	135.0M	148.0M	158.0M	123.0M
Advance Receipts	--	--	--	--	--
Contract Liabilities	38.3M	32.0M	28.7M	11.0M	16.5M
Total Current Liabilities	596.0M	661.0M	529.0M	432.0M	385.0M
Long Term Borrowings	35.9M	39.6M	--	--	--
Total Non Current Liabilities	106.0M	82.2M	43.7M	51.1M	50.3M
Total Liabilities	702.0M	743.0M	573.0M	484.0M	436.0M
Paid In Capital	177.0M	120.0M	120.0M	120.0M	120.0M
Capital Reserve	1.4B	1.4B	1.4B	1.4B	1.4B
Surplus Reserve	79.5M	60.0M	60.0M	60.0M	45.4M
Retained Earnings	1.1B	980.0M	820.0M	667.0M	486.0M
Equity Attributable	2.7B	2.6B	2.4B	2.3B	2.1B
Total Equity	2.7B	2.6B	2.4B	2.3B	2.1B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	1.4B	1.2B	1.2B	1.1B	958.0M
Tax Refunds Received	11.6M	33.0M	42.8M	18.9M	5.8M
Total Operating Cash Inflow	1.6B	1.3B	1.3B	1.2B	1.1B
Cash Paid For Goods	272.0M	181.0M	219.0M	150.0M	92.3M
Cash Paid To Employees	299.0M	296.0M	266.0M	250.0M	175.0M
Taxes Paid	159.0M	125.0M	151.0M	137.0M	124.0M
Total Operating Cash Outflow	1.3B	1.0B	1.1B	1.1B	920.0M
Operating Cash Flow	263.0M	275.0M	152.0M	148.0M	157.0M
Total Investing Cash Inflow	2.3B	3.0B	2.5B	4.2B	1.7B
Total Investing Cash Outflow	2.1B	3.4B	3.0B	4.3B	2.5B
Investing Cash Flow	197.0M	-410.0M	-406.0M	-111.0M	-757.0M
Cash From Borrowings	150.0M	235.0M	100.0M	30.0M	40.0M
Dividends And Interest Paid	74.1M	71.1M	96.0M	36.4M	696,300
Debt Repayments	254.0M	91.5M	50.0M	50.0M	--
Total Financing Cash Inflow	195.0M	245.0M	186.0M	30.0M	1.3B
Total Financing Cash Outflow	457.0M	164.0M	146.0M	86.4M	32.5M
Financing Cash Flow	-262.0M	80.7M	39.7M	-56.4M	1.3B
Net Change In Cash	198.0M	-54.3M	-214.0M	-19.4M	651.0M
Ending Cash Balance	965.0M	768.0M	822.0M	1.0B	1.1B
Capex	117.0M	175.0M	339.0M	256.0M	199.0M